ReviewCancers2023

Difference in Efficacy and Safety of Anti-CD19 Chimeric Antigen Receptor T-Cell Therapy Containing 4-1BB and CD28 Co-Stimulatory Domains for B-Cell Acute Lymphoblastic Leukemia.

Lijuan Wu et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.